Application of ⁶²Cu-Diacetyl-Bis (N⁴-Methylthiosemicarbazone) PET Imaging to Predict Highly Malignant Tumor Grades and Hypoxia-Inducible Factor-1α Expression in Patients with Glioma

References

1. 1.↵
   1. Ohgaki H,
   2. Kleihues P

   . Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479–89

   PubMedWeb of Science
2. 2.↵
   1. Louis DN,
   2. Ohgaki H,
   3. Wiestler OD,
   4. et al

   . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Jensen RL

   . Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 2006;20:E24

   CrossRefPubMed
4. 4.↵
   1. Jensen RL

   . Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009;92:317–35

   CrossRefPubMed
5. 5.↵
   1. Kayama T,
   2. Yoshimoto T,
   3. Fujimoto S,
   4. et al

   . Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg 1991;74:55–59

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Rampling R,
   2. Cruickshank G,
   3. Lewis AD,
   4. et al

   . Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994;29:427–31

   PubMedWeb of Science
7. 7.↵
   1. Swanson KR,
   2. Chakraborty G,
   3. Wang CH,
   4. et al

   . Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 2009;50:36–44

   Abstract/FREE Full Text
8. 8.↵
   1. Hirata K,
   2. Terasaka S,
   3. Shiga T,
   4. et al

   . (18)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging 2012 Feb 4 [Epub ahead of print]
9. 9.↵
   1. Sorger D,
   2. Patt M,
   3. Kumar P,
   4. et al

   . [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30:317–26

   CrossRefPubMed
10. 10.↵
    1. Shibahara I,
    2. Kumabe T,
    3. Kanamori M,
    4. et al

    . Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog. J Neurosurg 2010;113:358–68

    CrossRefPubMed
11. 11.↵
    1. Lewis JS,
    2. Sharp TL,
    3. Laforest R,
    4. et al

    . Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001;42:655–61

    Abstract/FREE Full Text
12. 12.↵
    1. Obata A,
    2. Yoshimi E,
    3. Waki A,
    4. et al

    . Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001;15:499–504

    CrossRefPubMedWeb of Science
13. 13.↵
    1. O'Donoghue JA,
    2. Zanzonico P,
    3. Pugachev A,
    4. et al

    . Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493–502

    CrossRefPubMed
14. 14.↵
    1. Dehdashti F,
    2. Grigsby PW,
    3. Lewis JS,
    4. et al

    . Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008;49:201–05

    Abstract/FREE Full Text
15. 15.↵
    1. Dehdashti F,
    2. Grigsby PW,
    3. Mintun MA,
    4. et al

    . Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response—a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233–38

    CrossRefPubMed
16. 16.↵
    1. Lewis JS,
    2. Laforest R,
    3. Dehdashti F,
    4. et al

    . An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008;49:1177–82

    Abstract/FREE Full Text
17. 17.↵
    1. Lohith TG,
    2. Kudo T,
    3. Demura Y,
    4. et al

    . Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med 2009;50:1948–53

    Abstract/FREE Full Text
18. 18.↵
    1. Minagawa Y,
    2. Shizukuishi K,
    3. Koike I,
    4. et al

    . Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 2011;25:339–45

    CrossRefPubMed
19. 19.↵
    1. Dence CS,
    2. Ponde DE,
    3. Welch MJ,
    4. et al

    . Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol 2008;35:713–20

    CrossRefPubMed
20. 20.↵
    1. Sheehan JP,
    2. Popp B,
    3. Monteith S,
    4. et al

    . Trans sodium crocetinate: functional neuroimaging studies in a hypoxic brain tumor. J Neurosurg 2011;115:749–53

    CrossRefPubMed
21. 21.↵
    1. Fujibayashi Y,
    2. Taniuchi H,
    3. Yonekura Y,
    4. et al

    . Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155–60

    Abstract/FREE Full Text
22. 22.↵
    1. Lewis JS,
    2. McCarthy DW,
    3. McCarthy TJ,
    4. et al

    . Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999;40:177–83

    Abstract/FREE Full Text
23. 23.↵
    1. Kato T,
    2. Shinoda J,
    3. Nakayama N,
    4. et al

    . Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008;29:1176–82

    Abstract/FREE Full Text
24. 24.↵
    1. Nariai T,
    2. Tanaka Y,
    3. Wakimoto H,
    4. et al

    . Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005;103:498–507

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Padma MV,
    2. Said S,
    3. Jacobs M,
    4. et al

    . Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227–37

    CrossRefPubMed
26. 26.↵
    1. Shinozaki N,
    2. Uchino Y,
    3. Yoshikawa K,
    4. et al

    . Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. J Neurosurg 2011;114:1640–47

    CrossRefPubMed
27. 27.↵
    1. Singhal T,
    2. Narayanan TK,
    3. Jain V,
    4. et al

    . 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008;10:1–18

    CrossRefPubMed
28. 28.↵
    1. Huang LE,
    2. Arany Z,
    3. Livingston DM,
    4. et al

    . Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996;271:32253–59

    Abstract/FREE Full Text
29. 29.↵
    1. Huang LE,
    2. Gu J,
    3. Schau M,
    4. et al

    . Regulation of hypoxia-inducible factor 1 alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998;95:7987–92

    Abstract/FREE Full Text
30. 30.↵
    1. Jiang BH,
    2. Semenza GL,
    3. Bauer C,
    4. et al

    . Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996;271:C1172–80

    Web of Science
31. 31.↵
    1. Weeks AJ,
    2. Paul RL,
    3. Marsden PK,
    4. et al

    . Radiobiological effects of hypoxia-dependent uptake of 64Cu-ATSM: enhanced DNA damage and cytotoxicity in hypoxic cells. Eur J Nucl Med Mol Imaging 2010;37:330–38

    CrossRefPubMed
32. 32.↵
    1. Skovgaard D,
    2. Kjaer M,
    3. Madsen J,
    4. et al

    . Noninvasive 64Cu-ATSM and PET/CT assessment of hypoxia in rat skeletal muscles and tendons during muscle contractions. J Nucl Med 2009;50:950–58

    Abstract/FREE Full Text
33. 33.↵
    1. Birner P,
    2. Preusser M,
    3. Gelpi E,
    4. et al

    . Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications. Clin Cancer Res 2004;10:6567–71

    Abstract/FREE Full Text
34. 34.↵
    1. Kaur B,
    2. Khwaja FW,
    3. Severson EA,
    4. et al

    . Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005;7:134–53

    Abstract/FREE Full Text
35. 35.↵
    1. Korkolopoulou P,
    2. Patsouris E,
    3. Konstantinidou AE,
    4. et al

    . Hypoxia-inducible factor 1 alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 2004;30:267–78

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Mashiko R,
    2. Takano S,
    3. Ishikawa E,
    4. et al

    . Hypoxia-inducible factor 1 alpha expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image. J Neurooncol 2011;102:43–50

    CrossRefPubMed
37. 37.↵
    1. Qiang L,
    2. Wu T,
    3. Zhang HW,
    4. et al

    . HIF-1 alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating notch signaling pathway. Cell Death Differ 2012;19:284–94

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Méndez O,
    2. Zavadil J,
    3. Esencay M,
    4. et al

    . Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Molecular Cancer 2010;9:133

    CrossRefPubMed
39. 39.↵
    1. Dreyfuss JM,
    2. Johnson MD,
    3. Park PJ

    . Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Molecular Cancer 2009;8:71

    CrossRefPubMed
40. 40.↵
    1. Irie N,
    2. Matsuo T,
    3. Nagata I

    . Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol 2004;21:1–6

    CrossRefPubMed
41. 41.↵
    1. Höckel M,
    2. Vaupel P

    . Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266–76

    Abstract/FREE Full Text
42. 42.↵
    1. Oh M,
    2. Tanaka T,
    3. Kobayashi M,
    4. et al

    . Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol 2009;36:419–26

    CrossRefPubMed
43. 43.↵
    1. Bar EE,
    2. Lin A,
    3. Mahairaki V,
    4. et al

    . Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 2010;177:1491–502

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Mathieu J,
    2. Zhang Z,
    3. Zhou W,
    4. et al

    . HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 2011;71:4640–52

    Abstract/FREE Full Text
45. 45.↵
    1. Zhou Y,
    2. Zhou Y,
    3. Shingu T,
    4. et al

    . Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem 2011;286:32843–53

    Abstract/FREE Full Text
46. 46.↵
    1. Wong TZ,
    2. Lacy JL,
    3. Petry NA,
    4. et al

    . PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. AJR Am J Roentgenol 2008;190:427–32

    CrossRefPubMed